Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Sees Significant Increase in Short Interest

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 73,100 shares, a growth of 28.7% from the June 15th total of 56,800 shares. Based on an average trading volume of 118,500 shares, the short-interest ratio is presently 0.6 days. Currently, 0.7% of the company’s shares are short sold.

Conduit Pharmaceuticals Stock Down 8.6 %

Shares of Conduit Pharmaceuticals stock traded down $0.02 during trading hours on Monday, reaching $0.24. 3,241,981 shares of the company were exchanged, compared to its average volume of 164,488. Conduit Pharmaceuticals has a 1 year low of $0.21 and a 1 year high of $25.00. The stock’s fifty day moving average is $2.04 and its 200 day moving average is $2.83.

Conduit Pharmaceuticals (NASDAQ:CDT) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.05) earnings per share for the quarter.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.